[维生素D和25-羟基维生素D3给药后人体血清25-羟胆钙化醇的行为]

[Behavior of serum 25-hydroxycholecalciferol in humans after administration of vitamin D and 25-OHD3].

作者信息

Coen G, Taccone Gallucci M, Bianchini G, Lucentini G, Gallucci G, Bianchi A R, Matteucci M C, Picca S, Casciani C U

出版信息

Boll Soc Ital Biol Sper. 1979 Oct 30;55(20):2051-6.

Abstract

Serum levels of 25 hydroxycholecalciferol were evaluated following i.m. and p.o. vit. D2 and D3 and p.o. 25OHD3 administration. While no increment in 25OHD3 serum levels were observed after i. m. administration of non-hydroxylated calciferols, a marked increment of the metabolite was found following the oral administration. However the peak values were largely impredictable. Acute and chronic p.o. administration of 25OHD3 determines a rapid and dose-dependent increase of the serum levels of the metabolite. In addition considering that a lower dosage is required of 25OHD3 compared to vit. D, this metabolite is preferable in the therapeutic use.

摘要

在肌肉注射和口服维生素D2、D3以及口服25羟胆钙化醇后，对血清25羟胆钙化醇水平进行了评估。肌肉注射非羟基化维生素D后，未观察到血清25羟胆钙化醇水平升高，而口服后该代谢产物水平显著升高。然而，峰值在很大程度上无法预测。急性和慢性口服25羟胆钙化醇可使该代谢产物的血清水平迅速且呈剂量依赖性升高。此外，考虑到与维生素D相比，25羟胆钙化醇所需剂量较低，因此该代谢产物在治疗应用中更具优势。